Additional file 1 of Hepatitis B, C and human immunodeficiency virus knowledge among the general greek population: results from the Hprolipsis nationwide survey

Additional file 1: Annex 1. Knowledge of HBV, HCV and HIV in the general adult Greek population: Questions and replies. Annex 2. Risk Factors Questions and replies

Summary of resistance results obtained by all methodologies.^a

a<p>Plasma samples underwent testing by Sanger sequencing (SS), allele-specific PCR (AS-PCR) and ultra-deep sequencing (UDS) targeting mutations in HIV-1 reverse transcriptase.</p

Factors associated with cause-specific hazard of initial virologic response and virologic failure after cART initiation.

1<p>: men having sex with men;²: injecting drug users;³: sex between men and women. Each factor is adjusted for all other factors in Table.</p>*<p>global Wald-type tests based on the fit of the corresponding models.</p

Predictors of virologic suppression <400 copies/ml 4–12 months after restarting NNRTI-based ART.^a

a<p>The analysis included 90 patients who restarted NNRTI-based ART without a protease inhibitor and had at least one viral load measurement in the 4–12 months after re-starting therapy.</p>b<p>As noted above some patients had the viral load measured by assays with a lower limit of quantification of either 75 or 400 copies/ml. NNRTI = non-nucleoside reverse transcriptase inhibitor; ART = antiretroviral therapy; OR = Odds ratio; CI = confidence interval.</p

Demographic and clinical characteristics of 1959 seroconverters from European and sub-Saharan African (SSA) cohorts.

<p>Numbers and percentage of respective populations given unless otherwise indicated;</p>*<p>Only for those with a “Midpoint” method of SC determination; IQR: Interquartile Range; SC: Seroconversion.</p

Estimated median (95% CI) CD4 cell count by HIV-1 subtype and time since cART initiation.

<p>(Non acute infection, without AIDS at cART initiation, boosted PI cART, seroconversion to cART >4 years, previously naïve, ≥5 log₁₀ c/ml initial viral load, men having sex with men, 30 years old at cART initiation).</p

Estimates from fitting a univariate (unadjusted) and a multivariable (adjusted) linear mixed model on all repeated measurements of CD4 cell counts (square root transformed) taken from seroconversion to end of follow-up, cART initiation or clinical AIDS onset.

*<p>Baseline category;</p>1<p>: Coefficients denote either mean estimated value for the reference category or mean estimated differences relative to the baseline category;</p>2<p>: Men of non-African origin in European cohorts;</p>3<p>: Individuals of non-African origin in European cohorts, aged 15–29 years at seroconversion and with a ≤6 months gap between seroconversion and study entry.</p

Cumulative incidence of initial virologic response (A) and virologic failure (B) by HIV-1 subtype.

<p>Numbers below each subfigure indicate numbers of individuals “at risk” (i.e. subjects not responded (A) or failed (B) and under follow-up).</p

Characteristics of the study population that interrupted NNRTI-based ART in SMART, according to the interruption modality.^a

a<p>Patients interrupted ART by simultaneously interrupting all drugs, continuing the nucleos(t)ide reverse transcriptase inhibitors (NRTIs) for a short period, or switching to a ritonavir-boosted protease inhibitor for a short period, referred to as simultaneous, staggered and switched interruption respectively.</p>b<p>In 46 patients the viral load was measured by assays with a lower limit of quantification of either 75 or 400 copies/ml and results were “undetectable” below these cut-offs; 19 patients showed a viral load between 50 and 400 copies/ml. NNRTI = non-nucleoside reverse transcriptase inhibitor; ART = antiretroviral therapy; MSM = Men who have sex with men; IQR = interquartile range.</p

Observed (A) and predicted (B) CD4 cell count by HIV-1 subtype.

<p>A: Median profiles (numbers on top indicate individuals contributing measurements at each time point), B: based on a piecewise linear mixed model (Non acute infection, without AIDS at cART initiation, boosted PI cART, SC to cART>4 years, previously naïve, 5 log₁₀ c/ml initial viral load, men having sex with men, 30 years old at cART initiation).</p